Pang Y P, Xu K, Kollmeyer T M, Perola E, McGrath W J, Green D T, Mangel W F
Mayo Clinic Cancer Center, Mayo Foundation for Medical Education and Research, Rochester, MN 55905, USA.
FEBS Lett. 2001 Aug 3;502(3):93-7. doi: 10.1016/s0014-5793(01)02672-2.
Using the computer docking program EUDOC, in silico screening of a chemical database for inhibitors of human adenovirus cysteine proteinase (hAVCP) identified 2,4,5,7-tetranitro-9-fluorenone that selectively and irreversibly inhibits hAVCP in a two-step reaction: reversible binding (Ki = 3.09 microM) followed by irreversible inhibition (ki = 0.006 s(-1)). The reversible binding is due to molecular complementarity between the inhibitor and the active site of hAVCP, which confers the selectivity of the inhibitor. The irreversible inhibition is due to substitution of a nitro group of the inhibitor by the nearby Cys122 in the active site of hAVCP. These findings suggest a new approach to selective, irreversible inhibitors of cysteine proteinases involved in normal and abnormal physiological processes ranging from embryogenesis to apoptosis and pathogen invasions.
使用计算机对接程序EUDOC,对化学数据库进行计算机模拟筛选以寻找人腺病毒半胱氨酸蛋白酶(hAVCP)的抑制剂,结果鉴定出2,4,5,7-四硝基-9-芴酮,其在两步反应中选择性且不可逆地抑制hAVCP:可逆结合(Ki = 3.09 microM),随后是不可逆抑制(ki = 0.006 s(-1))。可逆结合是由于抑制剂与hAVCP活性位点之间的分子互补性,这赋予了抑制剂的选择性。不可逆抑制是由于抑制剂的一个硝基被hAVCP活性位点附近的Cys122取代。这些发现提示了一种新方法,可用于开发参与从胚胎发生到细胞凋亡以及病原体入侵等正常和异常生理过程的半胱氨酸蛋白酶的选择性、不可逆抑制剂。